REFERENCES
1. European Association for the Study of the Liver. Corrigendum to “EASL Clinical Practice Guidelines: management of hepatocellular carcinoma”. J Hepatol 2018;69:182-236.
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
3. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF expanded criteria based on pre-operative imaging. Am J Transpl 2007;7:2587-96.
4. Herrero JI, Sangro B, Quiroga J, Pardo F, Herraiz M, et al. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 2001;7:631-6.
5. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded. A 22-year experience with 467 patients at UCLA. Ann Surg 2007;246:502-11.
6. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.
7. D’Amico F, Schwartz M, Vitale A, Tabrizian P, Roayaie S, et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl 2009;15:1278-87.
8. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 2007;25:310-2.
9. Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008;14:935-45.
10. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, et al; Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986-94.
11. Kaido T, Ogawa K, Mori A, Fujimoto Y, Ito T, et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery 2013;154:1053-60.
12. Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uchiyama H, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009;87:531-7.
13. Ito T, Takada Y, Ueda M, Haga H, Maetani Y, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 2007;13:1637-44.
14. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11-22.
15. Alshahrani AA, Ha SM, Hwang S, Ahn CS, Kim KH, et al. Clinical features and surveillance of very late hepatocellular carcinoma recurrence after liver transplantation. Ann Transplant 2018;23:659-65.
16. Chok KS, Chan SC, Cheung TT, Chan AC, Fan ST, et al. Late recurrence of hepatocellular carcinoma after liver transplantation. World J Surg 2011;35:2058-62.
17. Foerster F, Hoppe-Lotichius M, Vollmar J, Marquardt JU, Weinmann A, et al. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre. United European Gastroenterol J 2019;7:838-49.
18. Soin AS, Bhangui P, Kataria T, Baijal SS, Piplani T, et al. Experience with LDLT in patients with hepatocellular carcinoma and portal vein tumor thrombosis postdownstaging. Transplantation 2020; doi: 10.1097/TP.0000000000003162.
19. de’Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review. World J Gastroenterol 2015;21:11185-98.
20. Mazzaferro V, Sposito C, Zhou J, Pinna AD, De Carlis L, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology 2018;154:128-39.
21. Liang W, Wu L, Ling X, Schroder PM, Ju W, et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012;18:1226-36.
22. Fernandez-Sevilla E, Allard MA, Selten J, Golse N, Vibert E, et al. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection? Liver Transpl 2017;23:440-7.
23. Sapisochin G, Goldaracena N, Astete S, Laurence JM, Davidson D, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series. Ann Surg Oncol 2015;22:2286-94.
24. Kornberg A, Küpper B, Tannapfel A, Katenkamp K, Thrum K, et al. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol 2010;36:275-80.
25. Valdivieso A, Bustamante J, Gastaca M, Uriarte JG, Ventoso A, et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc 2010;42:660-2.
26. Escartin A, Sapisochin G, Bilbao I, Vilallonga R, Bueno J, et al. Recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc 2007;39:2308-10.
27. Kim HR, Cheon SH, Rha SY, Lee S, Han KH, et al. Treatment of recurrent hepatocellular carcinoma after liver transplantation. Asia Pac J Clin Oncol 2011;7:258-69.
28. Wang Y, Speeg KV, Washburn WK, Halff G. Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report. World J Gastroenterol 2010;16:5518-22.
29. Bhoori S, Toffanin S, Sposito C, Germini A, Pellegrinelli A, et al. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol 2010;52:771-75.
30. Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012;18:45-52.
31. Sposito C, Mariani L, Germini A, Reyes MF, Bongini M, et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol 2013;59:59-66.
32. Weinmann A, Niederle IM, Koch S, Hoppe-Lotichius M, Heise M, et al. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Dig Liver Dis 2012;44:432-37.
33. Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol 2010;40:768-73.
34. Geissler EK, Schnitzbauer AA, Zülke C, Lamby PE, Proneth A, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open- label phase 3 trial. Transplantation 2016;100:116-25.
35. Zhang ZH, Li LX, Li P, Lv SC, Pan B, et al. Sirolimus in liver transplant recipients with hepatocellular carcinoma: an updated meta-analysis. J Invest Surg 2019;32:632-41.
36. Jeng LB, Lee SG, Soin AS, Lee WC, Suh KS, et al. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant 2018;18:1435-46.
37. Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int 2014;27:1039-49.
38. Vivarelli M, Dazzi A, Zanello M, Cucchetti A, Cescon M, et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010;89:227-31.
39. Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 2008;40:3548-53.
40. Iavarone M, Invernizzi F, Czauderna C, Sanduzzi-Zamparelli M, Bhoori S, et al. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. Am J Transplant 2019;19:3176-84.
41. Kittai AS, Oldham H, Cetnar J, Taylor M. Immune checkpoint inhibitors in organ transplant patients. J Immunother 2017;40:277-81.
42. Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller C, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004;10:534-40.
43. Regalia E, Fassati LR, Valente U, Pulvirenti A, Damilano I, et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg 1998;5:29-34.
44. Bodzin AS, Lunsford KE, Markovic D, Harlander-Locke MP, Busuttil RW, et al. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics. Ann Surg 2017;266:118-25.
45. Invenizzi F, Iavarone M, Donato MF, Mazzucco A, Torre M, et al. Pulmonary resection for metastasis of hepatocellular carcinoma recurring after liver transplant: an Italian multicenter experience. Front Oncol 2020;10:381.
46. Tomimaru Y, Sasaki Y, Yamada T, Eguchi H, Takami K, et al. The significance of surgical resection for pulmonary metastasis from hepatocellular carcinoma. Am J Surg 2006;192:46-51.
47. Bates MJ, Farkas E, Taylor D, McFadden PM. Pulmonary resection of metastatic hepatocellular carcinoma after liver transplantation. Ann Thorac Surg 2008;85:412-5.
48. Hwang S, Kim YH, Kim DK, Ahn CS, Moon DB, et al. Resection of pulmonary metastases from hepatocellular carcinoma following liver transplantation. World J Surg 2012;36:1592-602.
49. Nakajima J, Tanaka M, Matsumoto J, Takeuchi E, Fukami T, et al. Appraisal of surgical treatment for pulmonary metastasis from hepatocellular carcinoma. World J Surg 2005;29:715-8.
50. Poon RT, Fan ST, O’Suilleabhain CB, Wong J. Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. J Am Coll Surg 2002;195:311-8.
51. O’Suilleabhain CB, Poon RT, Lau CW, Fan ST. Repeated resections of extrahepatic metastases after hepatic resection: an aggressive approach to hepatocellular carcinoma. Hepatogastroenterology 2004;51:825-9.
52. Gwak GY, Jung JO, Sung SW, Lee HS. Long-term survival after pulmonary metastatectomy of hepatocellular carcinoma; treatment outcome or natural history? Hepatogastroenterology 2004;51:1428-33.
53. Han KN, Kim YT, Yoon JH, Suh KS, Song JY, et al. Role of surgical resection for pulmonary metastasis of hepatocellular carcinoma. Lung Cancer 2010;70:295-300.
54. Aoki M, Hatayama Y, Kawaguchi H, Hirose K, Sato M, et al. Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study. J Radiat Res 2016;57:55-61.
55. Zhai H, Liang P, Yu XL, Cheng Z, Han ZY, et al. Microwave ablation in treating intrahepatic recurrence of hepatocellular carcinoma after liver transplantation: an analysis of 11 cases. Int J Hyperthermia 2015;31:863-8.
56. Ko HK, Ko GY, Yoon HK, Sung KB. Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation. Korean J Radiol 2007;8:320-7.
57. Rivera L, Giap H, Miller W, Fisher J, Hillebrand DJ, et al. Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report. World J Gastroenterol 2006;12:5729-32.
58. Huang J, Yan L, Wu H, Yang J, Liao M, et al. Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation? J Surg Res 2016;200:122-30.
59. Zhou B, Shan H, Zhu KS, Jiang ZB, Guan SH, et al. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation. J Vasc Interv Radiol 2010;21:333-8.
60. Toso C, Mentha G, Majno P. Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence. J Hepatol 2013;59:3-5.
61. Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol 2014;20:3100-11.
62. Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, et al. Stereotactic radiation therapy augments antigen-Specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 2015;3:345-55.
63. Parker JJ, Jones JC, Strober S, Knox SJ. Characterization of direct radiation-induced immune function and molecular signalling changes in an antigen presenting cell line. Clin Immunol 2013;148:44-55.
64. Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation. J Immunol 2012;189:558-66.
65. Pfiffer TEF, Seehofer D, Nicolaou A, Neuhaus R, Riess H, et al. Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era. Tumori 2011;97:436-41.
66. Roh YN, David Kwon CH, Song S, Shin M, Man Kim J, et al. The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant 2014;28:141-8.
